Literature DB >> 2106963

Promotion by the British pharmaceutical industry, 1983-8: a critical analysis of self regulation.

A Herxheimer1, J Collier.   

Abstract

Since 1958 the Association of the British Pharmaceutical Industry (ABPI) has attempted to regulate the promotion of prescription medicines through its code of practice. This regulation is described and analysed for the six years 1983-8 using the reports on 302 complaints considered by its code of practice committee and annual reports. The complaints came mainly from doctors (143, 48%) and competing companies (103, 33%). The committee found a total of 379 breaches of the code in 192 (63%) of the complaints. Additional breaches were detected by informational scrutiny of advertisements by the ABPI secretariat. Analysis showed that 270 (71%) of these breaches involved possible breaches of the Medicines Act. The rules that forbid misleading or unsubstantiated information and misleading claims or comparisons were broken most often. The committee found the most frequent offenders to be Organon (32 breaches), Smith Kline and French (23), Glaxo (21), A H Robins (18), Bayer (17), Merck Sharp and Dohme (17), and Lederle (16). Often the promotion of one product led to several breaches. The promotional wars over histamine H2 receptor antagonists accounted for 33 breaches. It is estimated that in 1983-8 about 100 breaches of the code were detected a year. In the 18 years 1972-88 the Medicines Act was breached probably over 1200 times. Health ministers, by not enforcing the regulations controlling promotion, have abrogated their responsibility to the ABPI, but the evidence suggests that the code has failed to deter promotional excesses. The ABPI's wish to secure compliance with the code seems weaker than its wish to pre-empt outside criticism and action: its self regulation seems to be a service to itself rather than to the public. It is suggested that the code of practice committee should become publicly accountable, that the majority of its members should represent the health professions and the public, and that effective sanctions are needed.

Entities:  

Mesh:

Year:  1990        PMID: 2106963      PMCID: PMC1661956          DOI: 10.1136/bmj.300.6720.307

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  3 in total

1.  Information contained in drug advertisements.

Authors:  G V Stimson
Journal:  Br Med J       Date:  1975-11-29

2.  Medicines Act passes crucial test.

Authors:  J Collier; A Herxheimer
Journal:  Lancet       Date:  1988-06-11       Impact factor: 79.321

3.  Laboratory testing on cerebrospinal fluid. A reappraisal.

Authors:  R A Hayward; M F Shapiro; R K Oye
Journal:  Lancet       Date:  1987-01-03       Impact factor: 79.321

  3 in total
  15 in total

1.  Selling drugs to the public--should the UK follow the example of the US?

Authors:  John Frey
Journal:  Br J Gen Pract       Date:  2002-02       Impact factor: 5.386

2.  Selling drugs to doctors--it's marketing, not education.

Authors:  Richelle Cooper; Jerome Hoffman
Journal:  Br J Gen Pract       Date:  2002-02       Impact factor: 5.386

3.  Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals.

Authors:  Alexander C Tsai
Journal:  Int J Health Serv       Date:  2003       Impact factor: 1.663

Review 4.  Drug utilisation review and pharmacoeconomics: interaction after parallel development?

Authors:  S Garattini; G Tognoni
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

Review 5.  Current prescribing in primary care in the UK. Effects of the indicative prescribing scheme and GP fundholding.

Authors:  T Walley; R Wilson; J Bligh
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 6.  'The strategy of desire' and rational prescribing.

Authors:  D K Scott; R E Ferner
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

7.  National Scientific Medical Meeting. The Royal College of Physicians of Ireland. Dublin, 8-9 April 1994. Abstracts.

Authors: 
Journal:  Ir J Med Sci       Date:  1994-04       Impact factor: 1.568

8.  Commercial source of drug information: comparison between the United Kingdom and India.

Authors:  R K Dikshit; N Dikshit
Journal:  BMJ       Date:  1994-10-15

9.  Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal.

Authors:  J Lexchin; A Holbrook
Journal:  CMAJ       Date:  1994-07-01       Impact factor: 8.262

Review 10.  Quality of pharmaceutical advertisements in medical journals: a systematic review.

Authors:  Noordin Othman; Agnes Vitry; Elizabeth E Roughead
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.